
    
      A 12-Week, Parallel-Group, Double-Blind, Randomized, Placebo-Controlled, Multicenter, Dose
      Ranging Study to Evaluate the Efficacy, Safety and Tolerability of GW823093, Administered
      Orally, Once Daily, as Monotherapy in Subjects With Type 2 Diabetes Mellitus followed by a
      12-week Active Treatment Extension
    
  